CTOs on the Move

Outpatient Imaging

www.outpatientimaging.net

 
Outpatient Imaging is a medical imaging center that offers a variety of diagnostic tests and procedures. Patients have the power to choose which imaging center performs their exam, as mandated by law in Georgia.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Petaluma Health Care District

Petaluma Health Care District is a Petaluma, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harlan, Heather

Harlan, Heather is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharma-Med

Pharma-Med Inc. is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Life Care Centers of America

Since our first facility opened in 1970, Life Care`s associates have positively impacted the company`s mission of providing exceptional patient care. Life Care owns or manages more than 200 facilities and employs approximately 40,000 individuals who strive daily to make a difference in the lives of those we serve. Our facilities offer multiple levels of patient care and services, which vary by location. We offer post-acute care and inpatient and outpatient therapy in well-equipped, on-site rehabilitation gyms. We believe that as a privately owned company, Life Care Centers of America stands apart from others. We offer a resident-centered corporate culture with more than 45 years of experience, stability and success. Our modern and well-maintained facilities feature strong multidisciplinary teams, specialty programs and opportunities for continuing education.

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.